Navigation Links
Arpida-Supported CME Symposium Available Online

REINACH, Switzerland, December 14 /PRNewswire-FirstCall/ -- As reported in September, Arpida Ltd. (SWX: ARPN) had a significant presence at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). A webcast of a CME accredited symposium at ICAAC, that was supported through an educational grant by Arpida, is available online at

The symposium is entitled "Treatment of Methicillin-resistant Staphylococcus aureus and Other Resistant Infections: An Expert Debate". In it distinguished speakers such as John G. Bartlett, MD, Louis B. Rice, MD, Dennis L. Stevens, PhD, MD, Gregory J. Moran, MD, FACEP and Robert C. Moellering, Jr., MD, MACP discuss the latest trends in their field. Topics include the increasing incidence of MRSA infections both in the healthcare setting and in the community, existing and emerging treatment options, as well as the changing landscape of bacterial resistance.

ICAAC is recognised as a premier global meeting for clinicians, researchers and scientists in the field of infectious diseases. In addition to the support of the CME symposium Arpida's participation comprised an exhibition booth which generated significant interest among the conference attendees as well as presentation of a total of 32 posters: 19 on the late-stage investigational antibiotic iclaprim and a total of 13 on AR-709 and AR-2474.

About the CME symposium

This CME (Continuing Medical Education) symposium should be seen as an educational activity, aimed primarily at healthcare professionals. Arpida Ltd. supported this educational activity through an unrestricted educational grant. The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Arpida Ltd., or the organisers. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed four Phase I trials. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam,

President and CEO

Tel: +41-61-417-96-60

Harry Welten, MBA,

CFO and Senior Vice President,

Tel: +41-61-417-96-65

Paul Verbraeken,

Head of Corporate Communications,

Tel: +41-61-417-96-83

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
2. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
5. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
6. Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium
7. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
8. Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium
9. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
10. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
11. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
Post Your Comments:
(Date:11/24/2015)... November 24, 2015 --> ... research report released by Transparency Market Research, the global ... a CAGR of 17.5% during the period between 2014 ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends ... prenatal testing market to reach a valuation of US$2.38 ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... environment are paramount. Insertion points for in-line sensors can represent a weak spot ... InTrac 781/784 series of retractable sensor housings , which are designed to ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):